The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

Provided herein are benzodiazepine analogs that are modified at the 7-position on the benzodiazepine ring to include a moiety selected from C.sub.2-C.sub.4 alkynyl, C.sub.3-C.sub.6 cycloalkyl, d(5)-cyclopropyl, methyl alkynyl, alkynyl-CD.sub.3, and alkynyl-CF.sub.3. Also provided are methods of use of the compounds in treating cancer, sensitizing a tumor to radiation, sensitizing a tumor to immunotherapy or chemotherapy, and treating neurological conditions associated with Type-A GABA neurotransmitter receptor function. Pharmaceutical compositions including the compounds are also provided.

Provided herein are benzodiazepine analogs that are modified at the 7-position on the benzodiazepine ring to include a moiety selected from C.sub.2-C.sub.4 alkynyl, C.sub.3-C.sub.6 cycloalkyl, d(5)-cyclopropyl, methyl alkynyl, alkynyl-CD.sub.3, and alkynyl-CF.sub.3. Also provided are methods of use of the compounds in treating cancer, sensitizing a tumor to radiation, sensitizing a tumor to immunotherapy or chemotherapy, and treating neurological conditions associated with Type-A GABA neurotransmitter receptor function. Pharmaceutical compositions including the compounds are also provided.